Risedronate therapy in patients with mild-to-moderate chronic kidney disease with osteoporosis: post-hoc analysis of...

Area of Science:

• Nephrology
• Endocrinology
• Rheumatology

Background:

• Limited data on bisphosphonate efficacy in Japanese Chronic Kidney Disease (CKD) patients with osteoporosis.
• This study analyzes Japanese phase III risedronate trials to evaluate treatment effects in CKD patients.

Purpose of the Study:

• To evaluate the clinical effect of risedronate therapy in Japanese osteoporosis patients with varying degrees of kidney function.
• To assess the safety and efficacy of risedronate in relation to estimated glomerular filtration rate (eGFR) levels.

Main Methods:

• Analysis of 852 Japanese subjects from three risedronate phase III trials.
• Subjects received risedronate (2.5 mg daily or 17.5 mg weekly) with eGFR ≥ 30 mL/min.
• Patients were categorized into eGFR subgroups (≥90, 60-89, 30-59 mL/min/1.73 m²); lumbar spine BMD, BTMs, and adverse events were assessed at 48 weeks.

Main Results:

• Risedronate administration demonstrated a significant increase in lumbar spine bone mineral density (BMD) across all eGFR subgroups.
• Bone turnover markers (BTMs) were significantly inhibited, indicating therapeutic effect.
• Adverse event incidence was comparable among subgroups, and no kidney function deterioration was observed in patients with eGFR > 30 mL/min/1.73 m².

Conclusions:

• Risedronate therapy is clinically effective for Japanese osteoporosis patients with CKD.
• The therapeutic effects of risedronate were consistent across different levels of kidney function.
• Risedronate is a safe and effective treatment option for osteoporosis in CKD patients with eGFR ≥ 30 mL/min/1.73 m².